<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491140</url>
  </required_header>
  <id_info>
    <org_study_id>ICH n. 380</org_study_id>
    <nct_id>NCT00491140</nct_id>
  </id_info>
  <brief_title>Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab</brief_title>
  <official_title>Retrospective Study Assessing Molecular Features Predicting Response or Resistance to Cetuximab Therapy in Metastatic Colorectal Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to identify molecular features predicting response or resistance to
      cetuximab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objective is to investigate association of genomic status of EGFR and HER-2 genes
      with clinical outcome, including objective response, time to progression and survival
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association of different biomarkers with Cetuximab sensitivity</measure>
    <time_frame>Assessment every two months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of different biomarkers with time to progression and survival</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">85</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Colorectal cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Gene mutations analysis and FISH</intervention_name>
    <description>FISH and mutation analysis of multiple genes</description>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Paraffine embedded tumor sections
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Colorectal cancer patients treated with Cetuximab
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of colorectal cancer with available tumor tissue
             and clinical data; presence of at least one measurable lesion.

        Exclusion Criteria:

          -  Less than 3 weeks after completion of previous radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005 Mar 20;23(9):1803-10. Epub 2005 Jan 27.</citation>
    <PMID>15677699</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2007</study_first_submitted>
  <study_first_submitted_qc>June 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2007</study_first_posted>
  <last_update_submitted>September 30, 2008</last_update_submitted>
  <last_update_submitted_qc>September 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Armando Santoro</name_title>
    <organization>Istituto Clinico Humanitas</organization>
  </responsible_party>
  <keyword>EGFR</keyword>
  <keyword>KRAS</keyword>
  <keyword>BRAF</keyword>
  <keyword>MET</keyword>
  <keyword>IGFR1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

